MedTrace Logo

Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

NCT00897065 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 957

Last updated 2013-07-10

No results posted yet for this study

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients respond to treatment.

PURPOSE: This laboratory study is looking at biomarkers that may predict response to tamoxifen and letrozole in postmenopausal women with primary breast cancer treated on clinical trial CAN-NCIC-MA17.

Conditions

Interventions

GENETIC

microarray analysis

GENETIC

polymerase chain reaction

GENETIC

protein expression analysis

OTHER

diagnostic laboratory biomarker analysis

OTHER

fluorescent antibody technique

OTHER

immunohistochemistry staining method

OTHER

immunologic technique

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Paul E. Goss, MD, PhD · Massachusetts General Hospital

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897065 on ClinicalTrials.gov